卵巣がん治療薬の市場規模、シェア、動向分析レポート：治療クラス別、治療別、最終用途別、地域別、セグメント別予測、2023年～2030年

卵巣がん治療薬市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、卵巣がん治療薬の世界市場規模は、2023年から2030年にかけて6.6%のCAGRを記録し、2030年には56億5,000万米ドルに達する見込みです。

同市場の成長は、新薬の採用増加や強力なパイプラインの存在といった要因によるところが大きいです。高齢者人口の増加や不健康なライフスタイルによる卵巣がんの罹患率の上昇が、市場を押し上げています。

卵巣がんは、女性の悪性腫瘍全体の3.0%、がんによる女性死亡者全体の6.0%を占める。卵巣がんは2016年に世界で235,200人の新規患者と140,000人の死亡者を占め、発生率は北米と欧州で最も高いと報告されています。

プラチナ製剤を使用しないPARP阻害剤とVEGF阻害剤のセカンドラインおよびサードラインでのイントロダクションより、卵巣がんの治療方針は劇的に変化しました。開発中の抗体薬物複合体（ADC）を含むいくつかの生物学的製剤や低分子療法は、卵巣がんの治療スペクトラムに大きな影響を与えると推定されます。

卵巣がん治療薬市場レポートハイライト

• 治療法に基づくと、病院薬局セグメントが2022年に45.37%の最大の売上シェアを占めました。がん研究・治療に対する政府の取り組みや資金提供の増加が薬剤開発とアクセシビリティを促進し、効果的な卵巣がん治療薬が病院内で入手できるようになっています。用途別では、商業用セグメントが2022年に88.0%と最大の売上シェアを占めました。これは、ジェネリック医薬品に対する需要の高まりによるもので、慢性疾患の負担が大きいことも成長の一因となっています。
• 例えば、オーストラリア連邦によると、2020年、オーストラリア政府は卵巣がん対策に特化した8つの研究プロジェクトに1,620万米ドルを割り当てた。オーストラリアでも世界全体でも、卵巣がんはすべての女性がんの中で一貫して最低の生存率を維持しています。平均すると、卵巣がんと診断された女性100人のうち43人が、診断から5年後に生存しています。
• オンライン薬局部門は、予測期間中最も速いCAGR 8.1％で成長すると予想されます。オンライン薬局が卵巣がん治療薬の注文と患者の自宅への直接配達を容易にすることで、特に健康上の制約がある患者の利便性が、卵巣がん治療薬市場におけるオンライン薬局セグメントの大きな促進要因となっています。このアクセシビリティは、必要不可欠な薬剤を入手する際の障壁を取り除き、患者の治療レジメンへのアドヒアランスを高め、これらの薬剤の市場リーチを拡大します。
• 例えば、AdooQ BioScience社は、顧客が卵巣がん治療薬、特にルカパリブを注文するのに便利なプラットフォームを提供しています。ウェブページ上で、顧客は医薬品の名称、説明、剤形、価格などの詳細情報にアクセスできます。
• 北米における卵巣がんの高い発生率は、効果的な治療法に対する重要かつ継続的な需要をもたらすため、この地域の卵巣がん治療薬市場の主要な促進要因であり、医薬品の研究や、多くの患者集団のニーズに対応するための技術革新を促進しています。
• 例えば、米国がん協会の2023年の米国における卵巣がんの予測によると、約19,710人の女性が新たに卵巣がんと診断され、約13,270人の女性が卵巣がんで命を落とすと予測されています。
• アジア太平洋地域では臨床試験への参加が増加しており、卵巣がん患者に最先端の治療法を提供するだけでなく、製薬企業や研究者を惹きつけることで医薬品開発を促進し、同地域の卵巣がん治療薬市場を発展させるため、予測期間中のCAGRは8.0%と最も早いと予想されます。*.
• 例えば、Clinical Trials Arenaによると、2017年から2022年にかけて、アジア太平洋地域では臨床試験が約10％増加し、米国や欧州などの他の主要地域で観察された成長率を上回る目覚ましい伸びを示しました。同地域のこの成長は、同期間の年平均5.3％を大幅に上回っています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 卵巣がん治療薬市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場促進要因の分析
  • 市場抑制要因分析
• 卵巣がん治療薬市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析

第4章 卵巣がん治療薬：治療クラス別推定・動向分析

• 卵巣がん治療薬市場：重要なポイント
• 卵巣がん治療薬市場：動向と市場シェア分析、2022年および2030年
• PARP阻害剤
• 血管新生阻害剤
• PD-L1阻害剤

第5章 卵巣がん治療薬：最終使用別推定・動向分析

• 卵巣がん治療薬市場：重要なポイント
• 卵巣がん治療薬市場：動向と市場シェア分析、2022年および2030年
• 病院薬局
• 小売薬局
• オンライン薬局

第6章 卵巣がん治療薬：治療別推定・動向分析

• 卵巣がん治療薬市場：重要なポイント
• 卵巣がん治療薬市場：動向と市場シェア分析、2022年および2030年
• 化学療法
• 放射線治療
• ホルモン療法
• 標的療法など

第7章 卵巣がん治療薬市場：地域別推定・動向分析

• 地域別の展望
• 地域別の卵巣がん治療薬市場：重要なポイント
• 北米
• 欧州
• アジア太平洋地域
• ラテンアメリカ
• 中東・アフリカ

第8章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 市場参入企業の分類
  • AbbVie Inc.
  • Pfizer, Inc.,
  • AstraZeneca,
  • F. Hoffmann-La Roche AG,
  • Johnson & Johnson Services, Inc.,
  • Boehringer Ingelheim International GmbH,
  • Clovis Oncology,
  • ImmunoGen, Inc.
  • Vivesto AB

List of Tables

• Table 1 List of Abbreviations
• Table 2 North America ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
• Table 3 North America ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
• Table 4 North America ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
• Table 5 North America ovarian cancer drugs market, by region, 2018 - 2030 (USD Million)
• Table 6 U.S. ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
• Table 7 U.S. ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
• Table 8 U.S. ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
• Table 9 Canada ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
• Table 10 Canada ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
• Table 11 Canada ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
• Table 12 Europe ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
• Table 13 Europe ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
• Table 14 Europe ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
• Table 15 Europe ovarian cancer drugs market, by region, 2018 - 2030 (USD Million)
• Table 16 Germany ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
• Table 17 Germany ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
• Table 18 Germany ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
• Table 19 UK ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
• Table 20 UK ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
• Table 21 UK ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
• Table 22 France ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
• Table 23 France ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
• Table 24 France ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
• Table 25 Italy ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
• Table 26 Italy ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
• Table 27 Italy ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
• Table 28 Spain ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
• Table 29 Spain ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
• Table 30 Spain ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
• Table 31 Sweden ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
• Table 32 Sweden ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
• Table 33 Sweden ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
• Table 34 Norway ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
• Table 35 Norway ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
• Table 36 Norway ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
• Table 37 Denmark ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
• Table 38 Denmark ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
• Table 39 Denmark ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
• Table 40 Asia Pacific ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
• Table 41 Asia Pacific ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
• Table 42 Asia Pacific ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
• Table 43 Asia Pacific ovarian cancer drugs market, by region, 2018 - 2030 (USD Million)
• Table 44 China ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
• Table 45 China ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
• Table 46 China ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
• Table 47 Japan ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
• Table 48 Japan ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
• Table 49 Japan ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
• Table 50 India ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
• Table 51 India ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
• Table 52 India ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
• Table 53 Thailand ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
• Table 54 Thailand ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
• Table 55 Thailand ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
• Table 56 South Korea ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
• Table 57 South Korea ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
• Table 58 South Korea ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
• Table 59 Latin America ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
• Table 60 Latin America ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
• Table 61 Latin America ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
• Table 62 Latin America ovarian cancer drugs market, by region, 2018 - 2030 (USD Million)
• Table 63 Brazil ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
• Table 64 Brazil ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
• Table 65 Brazil ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
• Table 66 Mexico ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
• Table 67 Mexico ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
• Table 68 Mexico ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
• Table 69 Argentina ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
• Table 70 Argentina ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
• Table 71 Argentina ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
• Table 72 Middle East and Africa ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
• Table 73 Middle East and Africa ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
• Table 74 Middle East and Africa ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
• Table 75 Middle East and Africa ovarian cancer drugs market, by region, 2018 - 2030 (USD Million)
• Table 76 South Africa ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
• Table 77 South Africa ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
• Table 78 South Africa ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
• Table 79 Saudi Arabia ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
• Table 80 Saudi Arabia ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
• Table 81 Saudi Arabia ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
• Table 82 UAE ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
• Table 83 UAE ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
• Table 84 UAE ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
• Table 85 Kuwait ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
• Table 86 Kuwait ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
• Table 87 Kuwait ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Market research approaches
• Fig. 5 Value-chain-based sizing & forecasting
• Fig. 6 QFD modeling for market share assessment
• Fig. 7 Market formulation & validation
• Fig. 8 Ovarian cancer drugs: Market outlook
• Fig. 9 Ovarian cancer drugs: Competitive insights
• Fig. 10 Parent market outlook
• Fig. 11 Related/ancillary market outlook
• Fig. 12 Penetration and growth prospect mapping
• Fig. 13 Industry value chain analysis
• Fig. 14 Ovarian cancer drugs market driver impact
• Fig. 15 Ovarian cancer drugs market restraint impact
• Fig. 16 Ovarian cancer drugs market strategic initiatives analysis
• Fig. 17 Ovarian cancer drugs market: Therapeutic Class movement analysis
• Fig. 18 Ovarian cancer drugs market: Therapeutic Class outlook and key takeaways
• Fig. 19 PARP inhibitors market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 20 Angiogenesis inhibitors market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 21 PD-L1 inhibitors market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 22 Ovarian cancer drugs market: Treatment movement analysis
• Fig. 23 Ovarian cancer drugs market: Treatment outlook and key takeaways
• Fig. 24 Hospital pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 25 Retail pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 26 Online pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 27 Ovarian cancer drugs market: End-use movement analysis
• Fig. 28 Ovarian cancer drugs market: End-use outlook and key takeaways
• Fig. 29 Chemotherapy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 30 Radiation therapy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 31 Hormonal therapy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 32 Targeted therapy & others market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 33 Global ovarian cancer drugs market: Regional movement analysis
• Fig. 34 Global ovarian cancer drugs market: Regional outlook and key takeaways
• Fig. 35 North America market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 36 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 37 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 38 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 39 UK market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 40 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 41 France market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 42 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 43 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 44 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 45 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 46 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 47 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 48 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 49 China market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 50 India market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 51 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 52 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 53 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 54 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 55 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 56 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 57 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 58 Middle East and Africa. market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 59 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 60 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 61 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 62 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)

Ovarian Cancer Drugs Market Growth & Trends:

The global ovarian cancer drugs market size is expected to reach USD 5.65 billion by 2030, registering a CAGR of 6.6% from 2023 to 2030, according to a new report by Grand View Research, Inc.. The growth of the market is largely driven by factors such as increased adoption of novel drugs and presence of strong pipeline. Rising incidence of ovarian cancer due to growing geriatric population and unhealthy lifestyles is providing an upthrust to the market.

Ovarian cancer accounts for 3.0% of all malignant tumors among women and 6.0% of all femaledeaths due to cancer. Ovarian cancer accounted for 235,200 new cases and 140,000 deaths worldwide in 2016 with the highest incidence being reported in North America and Europe.

Introduction of non-platinum based PARP inhibitors and VEGF inhibitors in second and third-line settings has changed the treatment regime for ovarian cancer dramatically. Several biologic and small-molecule therapies including antibody drug conjugates (ADC) in development are estimated to have a major impact on ovarian cancer treatment spectrum.

Ovarian Cancer Drugs Market Report Highlights:

• Based on treatment, the hospital pharmacy segment held the largest revenue share of 45.37% in 2022. An increasing number of government initiatives and funding for cancer research and treatment are driving drug development and accessibility, ensuring that effective ovarian cancer drugs are available in hospital settings. Based on application, the commercial segment dominated with the largest revenue share of 88.0% in 2022. This is due to the rising demand for generic drugs, and the high burden of chronic diseases are some factors contributing to the growth
• For instance, in 2020, according to the Commonwealth of Australia, the Australian Government allocated USD 16.2 million toward eight research projects dedicated to addressing ovarian cancer. In Australia or globally, ovarian cancer has consistently maintained the lowest survival rate among all female cancers. On average, 43 out of every 100 women diagnosed with ovarian cancer survived five years after their diagnosis.
• The online pharmacy segment is expected to grow at the fastest CAGR of 8.1% over the forecast period. The convenience of online pharmacies in facilitating the ordering and delivery of ovarian cancer drugs directly to patients' homes, particularly those with health limitations, is a significant driver of the online pharmacy segment in the ovarian cancer drugs treatment market. This accessibility eliminates barriers to obtaining essential medications, enhancing patient adherence to treatment regimens and expanding the market reach for these drugs.
• For instance, AdooQ BioScience provides a convenient platform for customers to order ovarian cancer drugs, specifically Rucaparib. On the webpage, customers can access detailed information about the drug, including its name, description, dosage forms, and pricing.
• North America dominated the industry with a market share of 43.47% in 2022 due to various factors, such as the high incidence of ovarian cancer in North America is a key driver of the region's ovarian cancer drugs market as it results in a significant and ongoing demand for effective treatments, fostering pharmaceutical research, and innovation to cater to the needs of the substantial patient population.
• For instance, according to the American Cancer Society's 2023 estimates for ovarian cancer in the United States, approximately 19,710 women are expected to be newly diagnosed, while approximately 13,270 women are projected to lose their lives to ovarian cancer. *
• Asia Pacific is expected to witness the fastest CAGR of 8.0% over the forecast period due to the increased participation in clinical trials in the region not only provides ovarian cancer patients with access to cutting-edge treatments but also fosters drug development by attracting pharmaceutical companies and researchers, thereby advancing the ovarian cancer drugs market in the region. *
• For instance, according to the Clinical Trials Arena, from 2017 to 2022, Asia Pacific experienced an impressive increase of approximately 10% in clinical trials, surpassing the growth rate observed in other major regions like the U.S. and Europe. This growth in the region significantly outpaced the overall average of 5.3% per year during the same period.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Therapeutic Class
  • 1.1.2. Treatment
  • 1.1.3. End-use
  • 1.1.4. Regional scope
  • 1.1.5. Estimates and forecast timeline
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
• 1.5. Market Formulation & Validation
• 1.6. Model Details
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Therapeutic class outlook
  • 2.2.2. Treatment outlook
  • 2.2.3. End-use outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Ovarian Cancer Drugs Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. Ovarian Cancer Drugs Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Ovarian Cancer Drugs: Therapeutic Class Estimates & Trend Analysis

• 4.1. Ovarian Cancer Drugs Market: Key Takeaways
• 4.2. Ovarian Cancer Drugs Market: Movement & Market Share Analysis, 2022 & 2030
• 4.3. PARP Inhibitors
  • 4.3.1. PARP inhibitors market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.4. Angiogenesis inhibitors
  • 4.4.1. Angiogenesis inhibitors market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.5. PD-L1 inhibitors
  • 4.5.1. PD-L1 inhibitors market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Ovarian Cancer Drugs: End-use Estimates & Trend Analysis

• 5.1. Ovarian Cancer Drugs Market: Key Takeaways
• 5.2. Ovarian Cancer Drugs Market: Movement & Market Share Analysis, 2022 & 2030
• 5.3. Hospital Pharmacy
  • 5.3.1. Hospital pharmacy market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.4. Retail pharmacy
  • 5.4.1. Retail pharmacy market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.5. Online Pharmacy
  • 5.5.1. Online pharmacy market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Ovarian Cancer Drugs: Treatment Estimates & Trend Analysis

• 6.1. Ovarian Cancer Drugs Market: Key Takeaways
• 6.2. Ovarian Cancer Drugs Market: Movement & Market Share Analysis, 2022 & 2030
• 6.3. Chemotherapy
  • 6.3.1. Chemotherapy market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.4. Radiation Therapy
  • 6.4.1. Radiation therapy market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.5. Hormonal Therapy
  • 6.5.1. Hormonal therapy market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.6. Targeted Therapy & others
  • 6.6.1. Targeted therapy & others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Ovarian Cancer Drugs Market: Regional Estimates & Trend Analysis

• 7.1. Regional Outlook
• 7.2. Ovarian Cancer Drugs Market by Region: Key Takeaway
• 7.3. North America
  • 7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.3.2. U.S.
    • 7.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.3.3. Canada
    • 7.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 7.4. Europe
  • 7.4.1. UK
    • 7.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.4.2. Germany
    • 7.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.4.3. France
    • 7.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.4.4. Italy
    • 7.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.4.5. Spain
    • 7.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.4.6. Sweden
    • 7.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.4.7. Norway
    • 7.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.4.8. Denmark
    • 7.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Japan
    • 7.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.5.2. China
    • 7.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.5.3. India
    • 7.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.5.4. Australia
    • 7.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.5.5. Thailand
    • 7.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.5.6. South Korea
    • 7.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 7.6. Latin America
  • 7.6.1. Brazil
    • 7.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.6.2. Mexico
    • 7.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.6.3. Argentina
    • 7.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 7.7. MEA
  • 7.7.1. Saudi Arabia
    • 7.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.7.2. South Africa
    • 7.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.7.3. UAE
    • 7.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.7.4. Kuwait
    • 7.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Market Participant Categorization
  • 8.2.1. AbbVie Inc.
    • 8.2.1.1. Company overview
    • 8.2.1.2. Financial performance
    • 8.2.1.3. Product benchmarking
    • 8.2.1.4. Strategic initiatives
  • 8.2.2. Pfizer, Inc.,
    • 8.2.2.1. Company overview
    • 8.2.2.2. Financial performance
    • 8.2.2.3. Product benchmarking
    • 8.2.2.4. Strategic initiatives
  • 8.2.3. AstraZeneca,
    • 8.2.3.1. Company overview
    • 8.2.3.2. Financial performance
    • 8.2.3.3. Product benchmarking
    • 8.2.3.4. Strategic initiatives
  • 8.2.4. F. Hoffmann-La Roche AG,
    • 8.2.4.1. Company overview
    • 8.2.4.2. Financial performance
    • 8.2.4.3. Product benchmarking
    • 8.2.4.4. Strategic initiatives
  • 8.2.5. Johnson & Johnson Services, Inc.,
    • 8.2.5.1. Company overview
    • 8.2.5.2. Financial performance
    • 8.2.5.3. Product benchmarking
    • 8.2.5.4. Strategic initiatives
  • 8.2.6. Boehringer Ingelheim International GmbH,
    • 8.2.6.1. Company overview
    • 8.2.6.2. Financial performance
    • 8.2.6.3. Product benchmarking
    • 8.2.6.4. Strategic initiatives
  • 8.2.7. Clovis Oncology,
    • 8.2.7.1. Company overview
    • 8.2.7.2. Financial performance
    • 8.2.7.3. Product benchmarking
    • 8.2.7.4. Strategic initiatives
  • 8.2.8. ImmunoGen, Inc.
    • 8.2.8.1. Company overview
    • 8.2.8.2. Financial performance
    • 8.2.8.3. Product benchmarking
    • 8.2.8.4. Strategic initiatives
  • 8.2.9. Vivesto AB
    • 8.2.9.1. Company overview
    • 8.2.9.2. Financial performance
    • 8.2.9.3. Product benchmarking
    • 8.2.9.4. Strategic initiatives